Results 1 to 10 of about 109,574 (350)

Immune cell labelling and tracking: implications for adoptive cell transfer therapies [PDF]

EJNMMI Radiopharmacy and Chemistry, 2021
Background The understanding of the role of different immune cell subsets that infiltrate tumors can help researchers in developing new targeted immunotherapies to reactivate or reprogram them against cancer.
Filippo Galli, Michela Varani, Chiara Lauri, Guido Gentiloni Silveri, Livia Onofrio, Alberto Signore   +5 more
doaj   +6 more sources

Anti-tumor efficacy of a combination therapy with PD-L1 targeted alpha therapy and adoptive cell transfer of PD-1 deficient melanoma-specific human T-lymphocytes [PDF]

OncoImmunology, 2021
The optimization of adoptive transfer approaches of anti-tumor T cells requires both the functional improvement of the injected T cells and the modulation of the tumor microenvironment, favoring the recruitment of these T cells and their activation.
L Marotte, M Capitao, C Deleine, T Beauvais, G Cadiou, J. Perrin, M Chérel, E Scotet, Y Guilloux, F Bruchertseifer, A Morgenstern, A Jarry, J. Gaschet, N Labarriere   +13 more
doaj   +2 more sources

New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer [PDF]

Journal of Translational Medicine, 2012
A summit on cellular therapy for cancer discussed and presented advances related to the use of adoptive cellular therapy for melanoma and other cancers. The summit revealed that this field is advancing rapidly.
Stroncek David F, Berger Carolina, Cheever Martin A, Childs Richard W, Dudley Mark E, Flynn Peter, Gattinoni Luca, Heath James R, Kalos Michael, Marincola Francesco M, Miller Jeffrey S, Mostoslavsky Gustavo, Powell Daniel J, Rao Mahendra, Restifo Nicholas P, Rosenberg Steven A, O'Shea John, Melief Cornelis JM   +17 more
doaj   +6 more sources

Improving Tumor Retention of Effector Cells in Adoptive Cell Transfer Therapies by Magnetic Targeting [PDF]

Pharmaceutics, 2020
Adoptive cell transfer therapy is a promising anti-tumor immunotherapy in which effector immune cells are transferred to patients to treat tumors. However, one of its main limitations is the inefficient trafficking of inoculated effector cells to the ...
Laura Sanz-Ortega, José Manuel Rojas, Domingo F. Barber   +2 more
doaj   +2 more sources

Metabolic radiolabeling and in vivo PET imaging of cytotoxic T lymphocytes to guide combination adoptive cell transfer cancer therapy [PDF]

Journal of Nanobiotechnology, 2021
Background Adoptive T cell transfer-based immunotherapy yields unsatisfactory results in the treatment of solid tumors, partially owing to limited tumor infiltration and the immunosuppressive microenvironment in solid tumors.
Dehua Lu, Yanpu Wang, Ting Zhang, Feng Wang, Kui Li, Shixin Zhou, Hua Zhu, Zhi Yang, Zhaofei Liu   +8 more
doaj   +2 more sources

Adoptive cell transfer: new perspective treatment in veterinary oncology [PDF]

Acta Veterinaria Scandinavica, 2018
Cancer immunotherapy is recently considered the most promising treatment for human patients with advanced tumors and could be effectively combined with conventional therapies such as chemotherapy or radiotherapy.
Joanna Katarzyna Bujak, Rafał Pingwara, Michelle Hase Nelson, Kinga Majchrzak   +3 more
doaj   +2 more sources

Adoptive cell transfer as personalized immunotherapy for human cancer. [PDF]

Science, 2015
Adoptive cell therapy (ACT) is a highly personalized cancer therapy that involves administration to the cancer-bearing host of immune cells with direct anticancer activity. ACT using naturally occurring tumor-reactive lymphocytes has mediated durable, complete regressions in patients with melanoma, probably by targeting somatic mutations exclusive to ...
Rosenberg SA, Restifo NP.
europepmc   +6 more sources

Focus on Adoptive T Cell Transfer Trials in Melanoma [PDF]

Clinical and Developmental Immunology, 2010
Adoptive Cell Transfer (ACT) of Tumor-Infiltrating Lymphocytes (TIL) in combination with lymphodepletion has proven to be an effective treatment for metastatic melanoma patients, with an objective response rate in 50%–70% of the patients.
Liat Hershkovitz, Jacob Schachter, Avraham J. Treves, Michal J. Besser   +3 more
doaj   +3 more sources

Is It Feasible to Use CMV-Specific T-Cell Adoptive Transfer as Treatment Against Infection in SOT Recipients?

Frontiers in Immunology, 2021
During the last decade, many studies have demonstrated the role of CMV specific T-cell immune response on controlling CMV replication and dissemination. In fact, it is well established that transplanted patients lacking CMV-specific T-cell immunity have ...
Estéfani García-Ríos, Marcos Nuévalos, Francisco J. Mancebo, Pilar Pérez-Romero   +3 more
doaj   +1 more source

Adoptive Cell Transfer Therapy [PDF]

Seminars in Oncology, 2007
Adoptive cell transfer therapy has developed into a potent and effective treatment for patients with metastatic melanoma. Current application of this therapy relies on the ex vivo generation of highly active, highly avid tumor-reactive lymphocyte cultures from endogenous tumor infiltrating lymphocytes or on the genetic engineering of cells using ...
Mark E, Dudley, Steven A, Rosenberg
openaire   +2 more sources